316 related articles for article (PubMed ID: 21132100)
1. Therapeutic Targeting of Myc.
Prochownik EV; Vogt PK
Genes Cancer; 2010 Jun; 1(6):650-659. PubMed ID: 21132100
[TBL] [Abstract][Full Text] [Related]
2. Stabilizers of the Max homodimer identified in virtual ligand screening inhibit Myc function.
Jiang H; Bower KE; Beuscher AE; Zhou B; Bobkov AA; Olson AJ; Vogt PK
Mol Pharmacol; 2009 Sep; 76(3):491-502. PubMed ID: 19498040
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts.
Berg T; Cohen SB; Desharnais J; Sonderegger C; Maslyar DJ; Goldberg J; Boger DL; Vogt PK
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3830-5. PubMed ID: 11891322
[TBL] [Abstract][Full Text] [Related]
4. Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription.
Struntz NB; Chen A; Deutzmann A; Wilson RM; Stefan E; Evans HL; Ramirez MA; Liang T; Caballero F; Wildschut MHE; Neel DV; Freeman DB; Pop MS; McConkey M; Muller S; Curtin BH; Tseng H; Frombach KR; Butty VL; Levine SS; Feau C; Elmiligy S; Hong JA; Lewis TA; Vetere A; Clemons PA; Malstrom SE; Ebert BL; Lin CY; Felsher DW; Koehler AN
Cell Chem Biol; 2019 May; 26(5):711-723.e14. PubMed ID: 30880155
[TBL] [Abstract][Full Text] [Related]
5. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.
Carabet LA; Lallous N; Leblanc E; Ban F; Morin H; Lawn S; Ghaidi F; Lee J; Mills IG; Gleave ME; Rennie PS; Cherkasov A
Eur J Med Chem; 2018 Dec; 160():108-119. PubMed ID: 30326371
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules.
Kiessling A; Sperl B; Hollis A; Eick D; Berg T
Chem Biol; 2006 Jul; 13(7):745-51. PubMed ID: 16873022
[TBL] [Abstract][Full Text] [Related]
7. Improved low molecular weight Myc-Max inhibitors.
Wang H; Hammoudeh DI; Follis AV; Reese BE; Lazo JS; Metallo SJ; Prochownik EV
Mol Cancer Ther; 2007 Sep; 6(9):2399-408. PubMed ID: 17876039
[TBL] [Abstract][Full Text] [Related]
8. Small-molecule perturbation of competing interactions between c-Myc and Max.
Follis AV; Hammoudeh DI; Daab AT; Metallo SJ
Bioorg Med Chem Lett; 2009 Feb; 19(3):807-10. PubMed ID: 19114306
[TBL] [Abstract][Full Text] [Related]
9. Thermodynamics of protein-protein interactions of cMyc, Max, and Mad: effect of polyions on protein dimerization.
Banerjee A; Hu J; Goss DJ
Biochemistry; 2006 Feb; 45(7):2333-8. PubMed ID: 16475822
[TBL] [Abstract][Full Text] [Related]
10. Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc.
Fieber W; Schneider ML; Matt T; Kräutler B; Konrat R; Bister K
J Mol Biol; 2001 Apr; 307(5):1395-410. PubMed ID: 11292350
[TBL] [Abstract][Full Text] [Related]
11. Thermodynamics of b-HLH-LZ protein binding to DNA: the energetic importance of protein-DNA contacts in site-specific E-box recognition by the complete gene product of the Max p21 transcription factor.
Meier-Andrejszki L; Bjelić S; Naud JF; Lavigne P; Jelesarov I
Biochemistry; 2007 Oct; 46(43):12427-40. PubMed ID: 17915948
[TBL] [Abstract][Full Text] [Related]
12. The Diarylheptanoid Curcumin Induces MYC Inhibition and Cross-Links This Oncoprotein to the Coactivator TRRAP.
Mödlhammer A; Pfurtscheller S; Feichtner A; Hartl M; Schneider R
Front Oncol; 2021; 11():660481. PubMed ID: 33937075
[TBL] [Abstract][Full Text] [Related]
13. AKT1, LKB1, and YAP1 Revealed as MYC Interactors with NanoLuc-Based Protein-Fragment Complementation Assay.
Mo X; Qi Q; Ivanov AA; Niu Q; Luo Y; Havel J; Goetze R; Bell S; Moreno CS; Cooper LA; Johns MA; Khuri FR; Du Y; Fu H
Mol Pharmacol; 2017 Apr; 91(4):339-347. PubMed ID: 28087810
[TBL] [Abstract][Full Text] [Related]
14. Design and properties of a Myc derivative that efficiently homodimerizes.
Soucek L; Helmer-Citterich M; Sacco A; Jucker R; Cesareni G; Nasi S
Oncogene; 1998 Nov; 17(19):2463-72. PubMed ID: 9824157
[TBL] [Abstract][Full Text] [Related]
15. The Max transcription factor network: involvement of Mad in differentiation and an approach to identification of target genes.
Hurlin PJ; Ayer DE; Grandori C; Eisenman RN
Cold Spring Harb Symp Quant Biol; 1994; 59():109-16. PubMed ID: 7587059
[TBL] [Abstract][Full Text] [Related]
16. The Quest for Targets Executing MYC-Dependent Cell Transformation.
Hartl M
Front Oncol; 2016; 6():132. PubMed ID: 27313991
[TBL] [Abstract][Full Text] [Related]
17. Low molecular weight inhibitors of Myc-Max interaction and function.
Yin X; Giap C; Lazo JS; Prochownik EV
Oncogene; 2003 Sep; 22(40):6151-9. PubMed ID: 13679853
[TBL] [Abstract][Full Text] [Related]
18. A credit-card library approach for disrupting protein-protein interactions.
Xu Y; Shi J; Yamamoto N; Moss JA; Vogt PK; Janda KD
Bioorg Med Chem; 2006 Apr; 14(8):2660-73. PubMed ID: 16384710
[TBL] [Abstract][Full Text] [Related]
19. Identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformation.
Mo H; Henriksson M
Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6344-9. PubMed ID: 16606833
[TBL] [Abstract][Full Text] [Related]
20. The MYCN oncoprotein as a drug development target.
Lu X; Pearson A; Lunec J
Cancer Lett; 2003 Jul; 197(1-2):125-30. PubMed ID: 12880971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
